

(12) **UK Patent Application** (19) **GB** (11) **2540694** (13) **A**

(43) Date of Reproduction by UK Office **25.01.2017**

(21) Application No: **1618524.1**
 (22) Date of Filing: **08.04.2015**
 Date Lodged: **03.11.2016**

(30) Priority Data:
 (31) **61985947** (32) **29.04.2014** (33) **US**
 (31) **62059723** (32) **03.10.2014** (33) **US**

(86) International Application Data:
PCT/US2015/024876 En 08.04.2015

(87) International Publication Data:
WO2015/167766 En 05.11.2015

(51) INT CL:
C12N 15/00 (2006.01) **A61K 38/00** (2006.01)
A61K 48/00 (2006.01) **C12N 5/071** (2010.01)

(56) Documents Cited:
WO 2014/039523 A1 **WO 2013/055908 A1**
US 20110158957 A1 **US 20090117097 A1**

(58) Field of Search:
 INT CL **A61K, C12N**
 Other: **PatSeer, Google, Google Scholar, Dialog ProQuest, Entrez PubMed, EBSCO**

(71) Applicant(s):
Seattle Children's Hospital (DBA Seattle Children's Research Institute)
1900 Ninth Avenue, Seattle, Washington, 98101, United States of America


(72) Inventor(s):
Thor Wagner
David J. Rawlings
Andrew M Scharenberg
Blythe Sather
Jaya Sahni

(74) Agent and/or Address for Service:
Withers & Rogers LLP
4 More London Riverside, LONDON, SE1 2AU, United Kingdom

(54) Title of the Invention: **CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies**
 Abstract Title: **CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies**

(57) The present application generally relates to methods of genetically modifying a T-cell comprising a chimeric antigen receptor wherein the T-cell lacks a co-receptor for HIV. The application further relates to methods of making a nucleic acid encoding a chimeric antigen receptor, nucleic acids encoding a chimeric antigen receptor, and genetically modified T-cells comprising a chimeric antigen receptor disclosed herein. The application further relates to methods of treating, inhibiting, or ameliorating HIV in a subject including administering to the subject a cell disclosed herein.

FIG. 1



GB 2540694 A